Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sernova Corp T.SVA

Alternate Symbol(s):  SEOVF

Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device. The Cell Pouch is designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells. Its regenerative medicine therapeutic approach is to provide cell therapies where the cells, transplanted within an organ-like vascularized implantable device, the Cell Pouch, generates proteins, hormones or factors released into the bloodstream for treatment of diseases requiring replacement of these molecules in the body.


TSX:SVA - Post by User

Bullboard Posts
Comment by elgin1on Jul 10, 2019 6:28pm
53 Views
Post# 29906237

RE:RE:RE:RE:RE:House Positions for SVA

RE:RE:RE:RE:RE:House Positions for SVA
BioTeck wrote: ViaCyte's PEC-Encap device ran into problems in 2016 and the trial was stopped. They have been working with W.L. Gore to try to improve the device and will be starting the trial fall 2019. This device doesn't require immuno suppression. Their PEC-Direct device requires immunosuppression and is comparable to Sernova's device. This hasn't run into fibrosis issues and clinical trials are happening in Canada, USA and started in Europe Jan of 2019. If results are good Sernova is toast.


Biohazard,

Your true colors are showing. You know every detail about Viacycte....  yet it is a private company that you cannot invest in.  Here you hope they have good results so Sva is toast.....  Sva pouch is not a one trick pony. It can be used for many indications Hemohilia, Thyroid, other potential stem cell and targeted drug delivery systems.  JDRF is not too keen on Viacycte.... ask them,,,, they favour Sernova and trust me they are familar with all the trials ongoing to treat diabetes. So tell me this BioDick,  when do you expect results from this trial?  I bet you are sitting on your hands and just waiting for it.   Why are you even here on this blog anatgonizing everybody?   

Sernova just needs resluts from a few more patients to validate that the pouch works and this not just a one off. I wonder if Viacycte device will cause weight loss ...... more like weight gain due to the fibrosis and bloating ...lol 

Bullboard Posts